Modified virus injected into tumors shows promise for liver cancer
NCT ID NCT00554372
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a modified virus called JX-594 (Pexa-Vec) in 30 people with liver cancer that could not be surgically removed. The virus was injected directly into the liver tumors to see if it could stop the cancer from growing. Researchers measured how many patients had their disease controlled at 8 weeks and checked for side effects at two different dose levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JX-594 (Pexa-Vec), a modified virus injected directly into tumors
What this could lead to
If successful, this could point toward a new way to control liver cancer that cannot be removed by surgery.
What could go wrong
This is a small, early-phase trial with only 30 participants. The virus may not shrink tumors or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Billings Clinic Cancer Center
Billings, Montana, 59101, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
McMaster University Medical Centre
Hamilton, Ontario, L8N 1Y3, Canada
-
Moores UCSD Cancer Center
La Jolla, California, 92093, United States
-
Pusan National University Hospital
Busan, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Shin Chon Severance Hospital / Yonsei University Medical Center
Seoul, South Korea
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
University of Pittsburgh Medical Center - Liver Cancer Center
Pittsburgh, Pennsylvania, 15213, United States